rAAV Production and Titration at the Microscale for High-Throughput Screening.


Journal

Human gene therapy
ISSN: 1557-7422
Titre abrégé: Hum Gene Ther
Pays: United States
ID NLM: 9008950

Informations de publication

Date de publication:
01 2022
Historique:
pubmed: 31 7 2021
medline: 1 2 2022
entrez: 30 7 2021
Statut: ppublish

Résumé

In the literature, there are few high-throughput screens or even methods for high-throughput screens of recombinant adeno-associated virus (rAAV) production despite potential benefits to research and production. In this study, a generalizable high-throughput relative rAAV titration method is examined within the context of an siRNA screen as siRNA knockdown is a common means of pathway engineering in bioproduction. Crude samples generated from transfected HEK293T/17 cultures were subjected to quantitative PCR (qPCR) and used to transduce COS7 cells to assess relative differences in genomic and infectious rAAV titer, respectively, at the 384-well scale, evaluating both supernatant and lysed samples. To evaluate relevant differences in titer for conditions that could be used in an actual screen, cultures subjected to an siRNA reverse transfection and subsequent rAAV forward transfection were also tested. The delayed forward rAAV triple-plasmid transfection was not seen to affect the siRNA activity of tested controls, while siRNA transfection was shown to measurably impact rAAV titer. Effective differentiation between infectious titer levels was dependent upon the choice of sample dilution, but trends between qPCR and infectious titer assays were consistent across sample sets.

Identifiants

pubmed: 34328798
doi: 10.1089/hum.2021.080
pmc: PMC8819507
doi:

Types de publication

Journal Article Research Support, N.I.H., Intramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

94-102

Références

PLoS One. 2020 Jul 24;15(7):e0236564
pubmed: 32706827
Hum Gene Ther. 2021 Aug;32(15-16):850-861
pubmed: 33397196
Biotechnol Bioeng. 2020 Oct;117(10):3199-3211
pubmed: 32573761
Hum Gene Ther. 2020 Apr;31(7-8):398-399
pubmed: 32302233
Mol Ther Methods Clin Dev. 2020 Sep 28;19:275-284
pubmed: 33102619
Proc Natl Acad Sci U S A. 2005 Sep 20;102(38):13634-9
pubmed: 16157891
Biomedicines. 2014 Mar 03;2(1):80-97
pubmed: 28548061
J Virol Methods. 2014 Feb;196:163-73
pubmed: 24239634
Hum Gene Ther Methods. 2019 Feb;30(1):23-33
pubmed: 30693792
Hum Gene Ther Methods. 2019 Aug;30(4):127-136
pubmed: 31140327
Biotechnol J. 2021 Jan;16(1):e2000025
pubmed: 32975881
Mol Ther Methods Clin Dev. 2016 Mar 16;3:16002
pubmed: 27014711
Curr Pharm Biotechnol. 2015;16(8):684-95
pubmed: 25941887
Mol Ther Methods Clin Dev. 2015 Jul 15;2:15024
pubmed: 26207258
J Virol. 1987 Apr;61(4):972-81
pubmed: 3029431
Hum Gene Ther Methods. 2014 Apr;25(2):115-25
pubmed: 24328707
Mol Ther Methods Clin Dev. 2018 Nov 01;11:180-190
pubmed: 30533449
Gene Ther. 2010 Apr;17(4):503-10
pubmed: 19956269
J Clin Microbiol. 2014 Dec;52(12):4361-2
pubmed: 25274992
Nucleic Acids Res. 2009 Apr;37(5):e40
pubmed: 19208643
Mol Ther Methods Clin Dev. 2019 Sep 26;15:257-263
pubmed: 31720304
Mol Ther Methods Clin Dev. 2018 Nov 22;13:14-26
pubmed: 30591923
J Biol Phys. 2018 Jun;44(2):181-194
pubmed: 29656365
J Invertebr Pathol. 2011 Jul;107 Suppl:S80-93
pubmed: 21784234
Mol Ther. 2018 Oct 3;26(10):2337-2356
pubmed: 30093306
Front Microbiol. 2019 Jul 17;10:1570
pubmed: 31379763
Virol J. 2013 Mar 06;10:74
pubmed: 23497173
Gene Ther. 2003 Dec;10(26):2105-11
pubmed: 14625564
Life Sci. 2021 Apr 1;270:119142
pubmed: 33524419
J Mol Biol. 2018 Aug 17;430(17):2626-2640
pubmed: 29782834
Hum Gene Ther Methods. 2017 Jun;28(3):139-147
pubmed: 28488944
Gene Ther. 2000 Jun;7(11):924-9
pubmed: 10849551
Mol Ther Methods Clin Dev. 2017 Dec 22;9:33-46
pubmed: 29349097
Biotechnol J. 2021 Jan;16(1):e2000015
pubmed: 33002276
Mol Ther Methods Clin Dev. 2020 Jun 10;18:328-334
pubmed: 32671135
Genes (Basel). 2020 Jun 18;11(6):
pubmed: 32570810
Proc Natl Acad Sci U S A. 2015 Sep 8;112(36):11276-81
pubmed: 26305933
Mol Ther. 2017 Dec 6;25(12):2661-2675
pubmed: 28890324
Mol Ther Methods Clin Dev. 2018 Jul 27;10:223-236
pubmed: 30112419

Auteurs

David Nathan Quan (DN)

NIDDK Biotechnology Core, NIDDK, National Institutes of Health, Bethesda, Maryland, USA.

Joseph Shiloach (J)

NIDDK Biotechnology Core, NIDDK, National Institutes of Health, Bethesda, Maryland, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH